Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.

Craig HaiferAshish Srinivasan Yoon-Kyo AnSherman PicardoDaniel van LangenbergShankar MenonJakob BegunSimon GhalyLena Thin

Published in: The Medical journal of Australia (2020)

Switching patients with IBD from originator to biosimilar infliximab is safe and non-inferior to continuing treatment with originator infliximab. Moreover, the introduction of biosimilar infliximab, by increasing market competition, has resulted in substantial cost savings for the Pharmaceutical Benefits Scheme.

Keyphrases

ulcerative colitis
early onset
randomized controlled trial
health insurance
high intensity
cross sectional